Search

The article focuses on the man named Naaman, who has expressed his gratitude to God after his leprosy was healed. It states that army commander Naaman had a leprosy which was cured by Elisha and Jesus, the prophets of Israel. It says that Naaman realized that in spite of trying to buy healing, the treatment has caused the transformation of his personality which provided him enlightenment. It adds that Naaman has glorified God with a loud voice, thanking Him for healing his inner and outer self. INSET: PRAYING WITH SCRIPTURE.

Discusses research being done on the occurrence of cholangitis while under the dapsone therapy for suspected leprosy. Reference to a study by S. Itha et al, published in the August 11, 2003 issue of the "BMC Gastroenterology"; Side effects that manifested after starting the dapsone treatment; Results of a liver biopsy and skin biopsy conducted for the patient; Treatment received by the patient.

Discusses the use of the medication thalidomide as a cancer treatment. How the drug caused deformations in babies when it was first used in Germany as an antihistamine; Consideration of how thalidomide can inhibit tumors directly as well as activate the immune system; Treatment of patients with multiple myeloma in London, England; Use of the drug to treat leprosy. INSET: A More Gentle Way.

Focuses on Thalomid, a brand name for thalidomide approved by the United States Food and Drug Administration for the treatment of erythema nodosum leprosum, a severe complication of leprosy. Risks of Thalomid; Effectiveness.

Reports on the United States Food and Drug Administration's approval of the drug, thalidomide in treating leprosy and cancer. Controversial uses of the drug as a sleeping pill and for morning sickness; Mayo Clinic doctors' study of the drug as treatment for multiple myeloma, a rare bone marrow cancer.

Reports on leprosy as being eliminated as a public health problem by the end of the century according to the World Health Organization (WHO). Funds to diagnose and cure patients over the next six years; Chief of WHO's leprosy unit; Multidrug therapy (MDT) as a combination of three drugs for milder cases reducing occurrence of disease; Accounts on presence of leprosy worldwide.

Reports on the World Health Organization's efforts to eliminate leprosy by the end of the twentieth century. Investment on multidrug therapies; Areas in the world most seriously affected; Care for disabilities resulting from bouts with leprosy.

Reports on the approval of thalidomide, a drug marketed as Thalomid by Celgene Corp., by the United States Food & Drug Administration (FDA). Basis for the treatment of a condition called erythema nodsum leprosum; Marketing restrictions against the drug due to reported birth defects; Reason for developing the System for Thalidomide Education and Prescribing Safety (STEPS); Other possible side effects of the intake of the drug.

Focuses on the `Hanoi Declaration on the Elimination of Leprosy.' The multidrug therapy recommended by the World Health Organization (WHO); The Conference on the Elimination of Leprosy; Contribution pledged by the Sasakawa Foundation.

Reports on the impending approval of the US Food and Drug Administration on the use of thalidomide for use in treating leprosy. Side effects of the drug; Other therapeutic effects of the drug.

Presents an excerpt from the April 1998 issue of `East African' which focuses on a multidrug therapy for leprosy.

Reports that the approval for the use of the drug thalidomide in the treatment of leprosy, was given by the United States Food and Drug Administration. How the drug works; Indication that this drug was under scrutiny; Reference to research to tests the effectiveness of the drug; Who will monitor the use of thalidomide.

Focuses on multidrug therapy (MDT), the combination of anti-leprosy drugs. Number of patients cured by the MDT since 1981; Committee and organizations supporting the paucibacillary (PB) leprosy patients; Implications of single-dose treatment for PB leprosy; Recommended standard treatment for MB leprosy since 1994.

Focuses on United States Food and Drug Administration's approval of drug firm Celgene Corp.'s plan to market thalidomide to treat a complication of leprosy.

Reports that the United States Food and Drug Administration (FDA) approved the drug called thalidomide in July 1998, in an effort to treat the disease known as leprosy. Information on the birth defects associated with the use of the drug; Details on other ailments which the drug was used to treat; Stipulations outlined by the FDA in relation to the use of the drug.

Reports on the approval of thalidomide as a treatment for leprosy victims in the United States.

Observes that the standard multi-drug therapy for multi-bacillary leprosy (MDT-MB) recommended by the World Health Organization proved effective in treating Lucio's phenomenon, a rare occurrence in patients with Lucio's leprosy. Description of Lucio's leprosy as "lepra bonita," or beautiful leprosy; Lucio's phenomenon as a reaction in patients with multi-bacillary leprosy that is triggered by other infections; Demonstration by two cases that clinical improvement can be attained using MDT-MB therapy.

Describes the experiences of patients with Hansen's disease at the Damien House, a facility in Guayaquil, Ecuador, that houses and treats Hansen's victims. Occurrence of the disease; Stigma associated with Hansen's disease; Residents' productive lives by creating crafts, dolls, peace bird ornaments and book markers.

Discloses that Celgene Corp. has received clearance from the United States Food and Drug Administration to market and sell thalidomide for the treatment of erythema nodosum leprosum.

Reports that the US Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee has recommended thalidomide for the treatment of complications of leprosy. Approval sought by Celgene Corp. to market thalidomide under the product name, Synovir.